Osimertinib Mesylate vs Trastuzumab
Osimertinib Mesylate vs Trastuzumab: Overview
This comparison examines the pharmacological differences between Osimertinib Mesylate and Trastuzumab.
Mechanism of Action
Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.
Pharmacokinetics
Half-life: Trastuzumab — 28 days.
Chemical Properties
Type: Osimertinib Mesylate — Small molecule; Trastuzumab — Antibody.